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Abstract
Background: Symptoms of spasmodic dysphonia (SD) are usually managed successfully with botulinum toxin injections. Vocal tremor (VT), which accompanies
SD, has a poor response to this treatment.
Case Report: We report a case of a female with SD and VT who became symptom-free for 10 months after the intake of a single dose of sodium oxybate
(XyremH). The long-term treatment effect correlated with attenuated brain activity in the key regions of dystonic brain network.
Discussion: Our case demonstrates that the novel treatment of sodium oxybate may hold promise for SD patients, especially those who have associated VT.
Keywords: Focal dystonia, treatment, brain modulation
Citation: Simonyan K, Frucht SJ. Long-term effect of sodium oxybate (XyremH) in spasmodic dysphonia with vocal tremor. Tremor Other Hyperkinet Mov
2013; 3: http://tremorjournal.org/article/view/206
* To whom correspondence should be addressed. E-mail: kristina.simonyan@mssm.edu
Editor: Elan D. Louis, Columbia University, United States of America
Received: October 9, 2013 Accepted: November 8, 2013 Published: December 9, 2013
Copyright: ’ 2013 Simonyan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which
permits the user to copy, distribute, and transmit the work provided that the original author(s) and source are credited; that no commercial use is made of the work; and that the work is not
altered or transformed.
Funding: National Institute on Deafness and other Communication Disorders, National Institutes of Health grant R01DC012545 to K.S. ClinicalTrials.gov Identifier: NCT01961297.
Financial Disclosure: None.
Conflict of Interest: The authors report no conflict of interest.
Introduction
Spasmodic dysphonia (SD), or laryngeal dystonia, is a primary focal
dystonia characterized by selective loss of voluntary voice control
during speaking due to uncontrolled spasms in the laryngeal muscles.
Voice tremor (VT) is characterized by rhythmic alterations in pitch
and loudness during vowel production and inability to sustain a vowel
for more than a few seconds. Combined SD/VT is a chronic
debilitating condition, which often extends beyond vocal communica-
tion impairment and causes significant occupational disability and life-
long social isolation. While symptoms of the adductor type of SD can
be managed with botulinum toxin injections for an average period of
3–4 months, VT has less predictable and poor results.1–3 Based on a
trial-and-error approach, some patients with SD and VT receive oral
medications, such as propranolol, primidone, clonazepam, and
lorazepam, which typically provide only mild short-term benefits.1,4
Case report
We report the case of a 38-year-old female with SD and VT who
became symptom-free for 10 months after the intake of a single dose of
sodium oxybate (XyremH). About 1.5 years prior to her visit with us,
she developed a strained, strangled voice with a mild tremor. Voice
breaks improved during singing at high pitches, laughing, and
whispering. Alcohol intake improved her voice by increasing the
volume and decreasing the tremor; however, symptoms returned after
the effect of alcohol had worn off. She was diagnosed with adductor
SD and VT 6 months after symptom onset by an experienced
laryngologist based on fiberoptic nasolaryngoscopy and videostrobo-
scopy, which revealed hyper-adduction and regular symmetrical
vibration of the vocal folds. Voice and speech therapy were not
beneficial. From the time of diagnosis up to the treatment with sodium
oxybate, the patient has received six botulinum toxin injections
bilaterally into the thyroarytenoid muscles (1.5 units/each) every 3
months, which were reportedly 90% effective for SD symptoms for a
period of 8 weeks; VT symptoms remained unaffected.
At the time of the visit, the patient was at the end of her botulinum
toxin treatment cycle. Her voice was mildly tremulous with straining,
strangulations, and moderate breaks on vowels. Her neurological
examinations did not reveal any dystonic postures in other body parts;
slight action tremor of the hands was observed. After obtaining written
informed consent for drug administration and follow-up magnetic
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resonance imaging (MRI), which was approved by the Institutional
Review Board of Mount Sinai School of Medicine, the patient received
1.0 g of sodium oxybate (XyremH) by mouth in the outpatient clinic as
part of an ongoing clinical research study. A clear audible
improvement of her voice was observed starting 20 minutes after
drug intake and was marked by an increase in the projecting volume
without voice breaks or tremor. On the visual analog scale from 1
(normal) to 10 (most difficult), the patient indicated that the effort of
speaking, crying, and shouting decreased from 9 to 2. Treatment-
related transient dizziness improved within 60 minutes of drug intake.
No adverse events, such as excessive sleepiness, depression, cardio-
pulmonary problems, cognitive impairment, or treatment-emergent
suicidality, were observed. Five hours after drug intake, the patient was
cognitively alert and stable, and her speech was not associated with
voice breaks or tremor. During follow-up phone calls on the day after
the visit and in the following 8 months, her voice remained without
SD-characteristic breaks or tremor. Her evaluation by us at 8 months
and by her laryngologist at 9 months after initial drug intake revealed
no signs of dystonic posture or tremor and there was a normal
laryngeal function with no evidence of adductor SD or VT. During
this period, the patient did not receive any additional treatment with
either botulinum toxin injections or sodium oxybate. She remained
symptom-free for a total of 10 months, before recurrence of SD voice
breaks following a stressful event. The patient took the second dose of
1.0 g of sodium oxybate and received benefits for 2 months. The third
intake of sodium oxybate (1.0 g) improved her voice for 24 hours with
some benefits lasting up to 1 week. At the time of submission of this
case, the effects of the most recent drug intake (1.0 g) have lasted for
over 1 month.
To examine the central effects of sodium oxybate, we performed a
functional MRI (fMRI) before the initial drug intake and about 90
minutes after the first drug intake as part of the ongoing research study.
Anatomical MRI was within the normal ranges without any gross
abnormalities. Pre-treatment fMRI was conducted before the initial drug
intake when the patient’s voice was fully symptomatic. Sentence
production showed bilaterally increased brain activity in the sensor-
imotor cortical regions, basal ganglia, and cerebellum (Figure 1A), which
was in line with abnormal brain activity found in larger studies in SD
patients.5,6 Post-treatment fMRI, which was conducted 90 minutes after
the drug intake when the patient had improved voice symptoms, showed
significantly attenuated brain activity in the primary sensorimotor cortex
(right.left), putamen, and cerebellum (Figure 1B). Because of unusually
lengthy drug benefits in this patient, we re-examined the effects of the
initial dose of sodium oxybate on brain activity at 8 months, when she
was still asymptomatic. The brain activity during speech production
remained attenuated in the basal ganglia and cerebellum with further
normalization of activity in the bilateral sensorimotor cortices compared
with the first post-treatment scan (Figure 1C).
Discussion
Our observation demonstrates that sodium oxybate significantly
improved voice symptoms in an ethanol-responsive SD/VT patient.
Although the limitation of this report is that such a lengthy effect of
sodium oxybate was observed in one patient only, another four patients
(two with abductor SD and two with isolated VT) who participated in our
study have reported treatment benefits lasting over 24 hours and up to 2
weeks after intake of 1.0 g of sodium oxybate. This duration of drug
Figure 1. Brain Activity During Production of English Sentences
Containing a Large Number of Vowels. Before treatment with sodium
oxybate (A), 90 minutes after treatment (B), and 8 months after treatment (C).
Brain activity is shown on the inflated brain surfaces in the standard Talairach–
Tournoux space and on the series of axial slices. The color bar represents t score.
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benefits is much longer than typical effects of sodium oxybate on dystonia
and tremor of about 3.5–4 hours.7,8 In the single patient reported here, a
long-term effect of sodium oxybate on SD/VT symptoms appeared to be
associated with a decrease (normalization) of brain overactivity in the key
regions within the dystonic brain network, possibly due to direct
modulation of abnormally increased5,6 brain activation during symptom
production. This may be due to the ability of sodium oxybate to mediate
gamma-aminobutic acid (GABA)-B receptor activation and metabolize
into GABA,9 the levels of which are known to be deficient in patients with
dystonia.10,11 It has been suggested that GABA-ergic deficiencies in
dystonia may contribute to the loss of inhibition and thus to the
generation of dystonic movements.12 Conversion of sodium oxybate into
GABA might have directly increased GABA levels and stabilized the
balance between excitation and inhibition within the sensorimotor
system.
A limitation of the study is that it was designed as an open-label trial
and hence the placebo effects of the drug cannot be ruled out.
Although the possibility exists that a sustained voice improvement in
this patient could be due to a placebo or psychogenic cause, the nature
of her voice disturbance, voice recordings, time course of improvement
with the drug, and correlation with imaging measures argue for a
biological cause. While we did not expect to see such long-term effects
in patients with SD and/or VT, this patient’s experience suggests that
sodium oxybate may be a promising pharmacological agent for
treatment of ethanol-responsive SD and VT patients. Further study of
its clinical and central effects is warranted.
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